Advertisement

Latest News

OUtMATCH: Omalizumab and OIT Similarly Enable Allergenic Food Consumption, With Robert Wood, MD

2 hours ago

Wood discussed the latest long term data from OUtMATCHat AAAAI 2026.

Discontinuing GLP-1 Treatment Associated With Up to 60% Weight Regain, With Brajan Budini

4 hours ago

Budini discusses his recent study investigating the trajectory of weight regain after GLP-1 cessation, given current high discontinuation rates.

6 Pulmonology Headlines You Missed in February 2026

5 hours ago

February 2026 saw new data and expert interviews from AAAAI 2026.

Lorundrostat Secures FDA NDA Acceptance for Hypertension, Falls Short in Phase 2 OSA Trial

5 hours ago

The FDA accepted Mineralys Therapeutics’ NDA for lorundrostat in hypertension, but the selective aldosterone synthase inhibitor fell short in a phase 2 obstructive sleep apnea trial.

RANIER: Povetacicept Achieves Primary and All Secondary Endpoints for IgAN

6 hours ago

Phase 3 RANIER exhibits positive results of Povetacicept in adults with IgA Nephropathy in a 36 week interim analysis,

Advertisement
Advertisement